{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 460777556
| IUPAC_name = 2-(difluoromethoxy)-1,1,1,2-tetrafluoro-ethane
| image = Desflurane2.svg
| image2 = Desflurane-3D-balls.png
<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status =  
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = Not metabolized
| elimination_half-life = Elimination dependent on minute ventilation
<!--Identifiers-->
| IUPHAR_ligand = 7156
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 57041-67-5
| ATC_prefix = N01
| ATC_suffix = AB07
| ATC_supplemental =  
| PubChem = 42113
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01189
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 38403
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = CRS35BZ94Q
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00546
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4445
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200733
<!--Chemical data-->
| C=3 | H=2 | F=6 | O=1
| molecular_weight = 168.038 g/mol
| smiles = FC(F)(F)C(F)OC(F)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DPYMFVXJLLWWEU-UHFFFAOYSA-N
}}

'''Desflurane''' (1,2,2,2-tetrafluoroethyl difluoromethyl ether) is a [[halogenated ether|highly fluorinated methyl ethyl ether]] used for maintenance of [[general anesthesia]]. Like [[halothane]], [[enflurane]], and [[isoflurane]], it is a [[racemic mixture]] of (''R'') and (''S'') optical isomers ([[Enantiomer|enantiomers]]). Together with [[sevoflurane]], it is gradually replacing [[isoflurane]] for human use, except in economically undeveloped areas, where its high cost precludes its use. It has the most rapid onset and offset of the [[volatile anesthetic]] drugs used for [[general anesthesia]] due to its low solubility in blood.

Some drawbacks of desflurane are its low potency, its pungency and its high cost (though at low flow fresh gas rates, the cost difference between desflurane and isoflurane appears to be insignificant<ref>{{cite web|author=John Varkey|title=Cost Analysis of Desflurane and Sevoflurane: An Integrative Review and Implementation Project Introducing the Volatile Anesthetic Cost Calculator|date=2012|url=http://crna.tcu.edu/wp-content/uploads/Varkey-J.-Cost-Analysis-of-Desflurane-and-Sevoflurane-An-Integrative-Review-and-Implementation-Project-Introducing-the-Volatile-Anesthetic-Cost-Calculator-iVAC%C2%A9.pdf}}</ref>. It may cause [[tachycardia]] and airway irritability when administered at concentrations greater than 10 vol%.  Due to this airway irritability, desflurane is infrequently used to induce anesthesia via inhalation techniques.

Though it vaporises very readily, it is a liquid at room temperature. [[Anaesthetic machine]]s are fitted with a specialized [[anaesthetic vaporiser]] unit that heats liquid desflurane to a constant temperature.  This enables the agent to be available at a constant vapor pressure, negating the effects fluctuating ambient temperatures would otherwise have on its concentration imparted into the fresh gas flow of the anesthesia machine.

Desflurane, along with [[enflurane]] and to a lesser extent [[isoflurane]], has been shown to react with the [[carbon dioxide]] absorbent in anesthesia circuits to produce detectable levels of [[carbon monoxide]] through degradation of the anesthetic agent.  The {{CO2}} absorbent [[Baralyme]], when dried, is most culpable for the production of carbon monoxide from desflurane degradation, although it is also seen with [[soda lime]] absorbent as well. Dry conditions in the carbon dioxide absorbent are conducive to this phenomenon, such as those resulting from high fresh gas flows.<ref>{{cite web |url=http://www.anesthesia-analgesia.org/cgi/reprint/80/6/1187.pdf |title=Carbon Monoxide Production from Degradation of Desflurane |author=Fang |year=1995 |publisher=Anesthesia and Analgesia |display-authors=etal}}</ref>

==Pharmacology==
Desflurane is known to act as a [[positive allosteric modulator]] of the [[GABAA receptor|GABA<sub>A</sub>]] and [[glycine receptor]]s,<ref name="HemmingsHopkins2006">{{cite book|author1=Hugh C. Hemmings|author2=Philip M. Hopkins|title=Foundations of Anesthesia: Basic Sciences for Clinical Practice|url=https://books.google.com/books?id=xaXu1wHmENoC&pg=PA290|year=2006|publisher=Elsevier Health Sciences|isbn=0-323-03707-0|pages=290–291}}</ref><ref name="MillerEriksson2014">{{cite book|author1=Ronald D. Miller|author2=Lars I. Eriksson|author3=Lee A Fleisher |author4=Jeanine P. Wiener-Kronish |author5=Neal H Cohen |author6=William L. Young|title=Miller's Anesthesia|url=https://books.google.com/books?id=L2ckBQAAQBAJ&pg=PA624|date=20 October 2014|publisher=Elsevier Health Sciences|isbn=978-0-323-28011-2|pages=624–}}</ref> and as a [[negative allosteric modulator]] of the [[nicotinic acetylcholine receptor]],<ref name="ReedYudkowitz2013">{{cite book|author1=Allan P. Reed|author2=Francine S. Yudkowitz|title=Clinical Cases in Anesthesia|url=https://books.google.com/books?id=9VVJAgAAQBAJ&pg=PA101|date=2 December 2013|publisher=Elsevier Health Sciences|isbn=978-0-323-18654-4|pages=101–}}</ref><ref name="BarashCullen2013">{{cite book|author1=Paul Barash|author2=Bruce F. Cullen|author3=Robert K. Stoelting |author4=Michael Cahalan |author5=Christine M. Stock |author6=Rafael Ortega|title=Clinical Anesthesia, 7e: Print + Ebook with Multimedia|url=https://books.google.com/books?id=exygUxEuxnIC&pg=PA470|date=7 February 2013|publisher=Lippincott Williams & Wilkins|isbn=978-1-4698-3027-8|pages=470–}}</ref> as well as affecting other [[ligand-gated ion channel]]s.<ref name="CotéLerman2013">{{cite book|author1=Charles J. Coté|author2=Jerrold Lerman|author3=Brian J. Anderson|title=A Practice of Anesthesia for Infants and Children: Expert Consult - Online and Print|url=https://books.google.com/books?id=MAXTnQStL0cC&pg=PA499|year=2013|publisher=Elsevier Health Sciences|isbn=1-4377-2792-1|pages=499–}}</ref><ref name="AglioLekowski2015">{{cite book|author1=Linda S. Aglio|author2=Robert W. Lekowski|author3=Richard D. Urman|title=Essential Clinical Anesthesia Review: Keywords, Questions and Answers for the Boards|url=https://books.google.com/books?id=VJzWBQAAQBAJ&pg=PA128|date=8 January 2015|publisher=Cambridge University Press|isbn=978-1-107-68130-9|pages=128–}}</ref>

==Physical properties==
{|
|[[Boiling point]] : ||align=right| 23.5&nbsp;°C  or 74.3&nbsp;°F ||(at 1 [[atmosphere (unit)|atm]])
|-
|[[Density]] : || 1.465 g/cm³|| (at 20&nbsp;°C)
|-
|[[Molecular Weight]] : ||align=right| 168||
|-
|[[Vapor pressure]]: ||align=right| 88.5 kPa ||align=right| 672 mmHg|| (at 20&nbsp;°C)
|-
| ||align=right| 107 kPa ||align=right|804 mmHg || (at 24&nbsp;°C)
|-
|[[blood/gas partition coefficient|Blood:Gas partition coefficient]]: ||align=right|  0.42 ||
|-
| Oil:Gas partition coefficient : ||align=right|  19 ||
|-
|[[Minimum alveolar concentration|MAC]] : ||align=right|  6 vol % ||
|-
|}

==Global-warming potential==
Desflurane is a [[greenhouse gas]]. The twenty-year [[global-warming potential]], GWP(20), for desflurane is 3714,<ref name = GWP>{{cite journal | last = Ryan | first = Susan M. | authorlink =  |author2=Nielsen, Claus J. | title = Global Warming Potential of Inhaled Anesthetics: Application to Clinical Use | journal = [[Anesthesia & Analgesia]] | volume = 111 | issue = 1 | pages = 92–98 | publisher = [[International Anesthesia Research Society]] | location = San Francisco, CA | date = July 2010 | url = http://www.anesthesia-analgesia.org/content/111/1/92.long | issn =  | doi = 10.1213/ane.0b013e3181e058d7| id =  | accessdate =9 September 2011}}</ref> meaning that one tonne of desflurane emitted is equivalent to 3714 tonnes of [[carbon dioxide]] in the atmosphere, much higher than [[sevoflurane]] or [[isoflurane]]. In addition to [[global warming potential]]s, drug potency and fresh gas flow rates must be considered for meaningful comparisons between anesthetic gases.  When a steady state hourly amount of anesthetic necessary for 1 minimum alveolar concentration (MAC) at 2 liters per minute (LPM) for Sevoflurane, and 1 LPM for Desflurane and Isoflurane is weighted by the GWP, the clinically relevant quantities of each anesthetic can then be compared. On a per-MAC-hour basis, the total life cycle GHG impact of desflurane is more than 20 times higher than Isoflurane and Sevoflurane (1 [[minimal alveolar concentration]]-hour).<ref>{{cite journal |vauthors=Sherman J, Le C, Lamers V, Eckelman M |title=Life Cycle Greenhouse Gas Emissions of  Anesthetic Drugs |journal=Anesthesia and Analgesia|volume=114 |issue=5  |pages=1086–1090 |date=May 2012|url=http://journals.lww.com/anesthesia-analgesia/Fulltext/2012/05000/Life_Cycle_Greenhouse_Gas_Emissions_of_Anesthetic.25.aspx|doi=10.1213/ANE.0b013e31824f6940}}</ref> One paper finds anesthesia gases used globally contribute the equivalent of 1 million cars to [[global warming]].<ref>{{cite journal |vauthors=Sulbaek Andersen MP, Sander SP, Nielsen OJ, Wagner DS, Sanford Jr TJ, Wallington TJ |title=Inhalation anaesthetics and climate change |journal=British Journal of Anaesthesia|volume=105 |issue=6  |pages=760–766 |date=July 2010|doi= 10.1093/bja/aeq259 |url=http://bja.oxfordjournals.org/content/105/6/760.abstract }}</ref> This estimate is commonly cited as a reason to neglect pollution prevention by anesthesiologists, however this is problematic. This estimate is extrapolated from only one U.S. institution’s anesthetic practices, and this institution uses virtually no Desflurane. Researchers neglected to include nitrous oxide in their calculations, and reported an erroneous average of 17 kg CO2e per anesthetic. However, institutions that utilize some Desflurane and account for nitrous oxide have reported an average of 175-220 kg CO2e per anesthetic. Sulbaek-Anderson’s group therefore likely underestimated the total worldwide contribution of inhaled anesthetics, and yet still advocates for inhaled anesthetic emissions prevention.<ref name="Scientific Abstracts 2014">{{cite web|last1=Sherman|first1=J|title=Estimate of Carbon Dioxide Equivalents of Inhaled Anesthetics in the United States|url=http://www.asaabstracts.com/strands/asaabstracts/printAbstract.htm;jsessionid=491932CB9B03D78ECF6AA62FAAA0C61A?index=0&type=search&absnum=0&year=2005|website=American Society of Anesthesiologists|publisher=American Society of Anesthesiologists|accessdate=June 3, 2015}}</ref>

== Research==
A 2014 clinical study found that desflurane has lower [[bispectral index]] and greater hypnotic effect than [[sevoflurane]] during the equipotent anesthesia.<ref name=" pmid = 24366495 ">{{cite journal | author = Kim JK | title = Relationship of bispectral index to minimum alveolar concentration during isoflurane, sevoflurane or desflurane anaesthesia. | journal = J Int Med Res | volume = 42 | issue = 1|date=Feb 2014 | pmid = 24366495 | url = http://imr.sagepub.com/content/42/1/130.long | pages = 130–7 | doi=10.1177/0300060513505525}}</ref>{{contradict-inline|article=sevoflurane|July 2015|date=January 2016}}

==References==
{{reflist|30em}}

===Book references and additional reading===
* Eger, Eisenkraft, Weiskopf. ''The Pharmacology of Inhaled Anesthetics''. 2003.
* Rang, Dale, Ritter, Moore. ''Pharmacology 5th Edition''. 2003.
* Martin Bellgardt: ''Evaluation der Sedierungstiefe und der Aufwachzeiten frisch operierter Patienten mit neurophysiologischem Monitoring im Rahmen der Studie: Desfluran versus Propofol zur Sedierung beatmeter Patienten.'' Bochum, Dissertation, 2005 ([https://web.archive.org/web/20110522081443/http://deposit.ddb.de/cgi-bin/dokserv?idn=977851818&dok_var=d1&dok_ext=pdf&filename=977851818.pdf pdf])
* Susanne Lohmann: ''Verträglichkeit, Nebenwirkungen und Hämodynamik der inhalativen Sedierung mit Desfluran im Rahmen der Studie: Desfluran versus Propofol zur Sedierung beatmeter Patienten.'' Bochum, Dissertation, 2006 ([http://www-brs.ub.ruhr-uni-bochum.de/netahtml/HSS/Diss/LohmannSusanne/diss.pdf pdf])
* Patel SS, Goa KL. (1995) "Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia." ''Drugs'' Oct;50(4):742-67. {{PMID|8536556}}.

{{General anesthetics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{GABAA receptor modulators}}
{{Glycine receptor modulators}}
{{Nicotinic acetylcholine receptor modulators}}
}}

[[Category:General anesthetics]]
[[Category:Ethers]]
[[Category:Organofluorides]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Glycine receptor agonists]]
[[Category:Nicotinic antagonists]]
[[Category:Fluranes]]
[[Category:Trifluoromethyl compounds]]